Influence of IL10 Gene polymorphisms on the sustained virologic response of patients with chronic hepatitis C to PEG-interferon/ribavirin therapy.
There are accurate but inconclusive data on the association of interleukin (IL) 10 polymorphisms with sustained virological response (SVR) in chronic hepatitis C (CHC). This meta-analysis aimed to derive a more precise estimation of the effects of IL10 gene polymorphisms (-1082G/A, -819C/T, -592C/A) and their haplotypes on SVR in CHC patients receiving pegylated interferon alpha (PEG-IFN-a) plus ribavirin. Literature search was conducted up to Jan., 2016, in PubMed, EMBASE and ISI Web of Science electronic databases. Statistical analyses were performed by STATA11.0 software, with odds ratios (ORs) and their 95% confidence intervals (CIs). A total of 14 studies involving 1687 CHC cases met the inclusion criteria. Analyses were stratified either by ethnicity or genotype of hepatitis C virus (HCV). The results indicated that IL10-1082A/G was associated with a significantly decreased SVR rate based on the heterozygous model (OR: 0.662, 95% CI: 0.467-0.938) and dominant model (OR: 0.648, 95% CI: 0.440-0.955). Similar results were found in the Egyptian and HCV-4 genotype in all gene models except the recessive model. Moreover, we observed that IL10-819T allele carriers was associated with a significantly increased SVR in the Caucasian population (OR: 1.380, 95% CI: 1.018-1.871). However, we did not detect any significant association of the -592C/A polymorphism or haplotypes with SVR in the total or subgroup populations. In conclusion, IL10-1082GG genotype and -1082G allele were associated with decreased SVR rate in CHC patients, especially for the Egyptian and HCV-4 genotype. Moreover, IL10-819T allele was more likely to get SVR in the Caucasian population.